Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vaccination to Enhance the Anti-Tumor Activity of GD2 Chimeric Antigen Receptor-Expressing, VZV-Specific T Cells in Subjects With Advanced Sarcomas and Neuroblastoma (VEGAS)

NCT01953900 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT01953900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01953900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vaccination to Enhance the Anti-Tumor Activity of GD2 Chimeric Antigen Receptor-Expressing, VZV-Specific T Cells in Subjects With Advanced Sarcomas and Neuroblastoma (VEGAS)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 30, 2014
Completion date
October 31, 2034
Enrollment
26 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma, osteosarcoma